Man Group plc Makes New Investment in Teladoc Health, Inc. $TDOC

Man Group plc purchased a new stake in shares of Teladoc Health, Inc. (NYSE:TDOC) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 811,385 shares of the health services provider’s stock, valued at approximately $6,881,000. Man Group plc owned about 0.45% of Teladoc Health at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Allworth Financial LP acquired a new stake in shares of Teladoc Health during the 2nd quarter worth approximately $25,000. IFP Advisors Inc lifted its holdings in Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares during the period. EFG International AG bought a new position in Teladoc Health in the second quarter valued at approximately $35,000. PNC Financial Services Group Inc. boosted its stake in Teladoc Health by 177.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 2,810 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Teladoc Health by 694.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after acquiring an additional 4,945 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

Insider Transactions at Teladoc Health

In related news, CEO Charles Divita III sold 19,132 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $145,977.16. Following the sale, the chief executive officer owned 389,894 shares of the company’s stock, valued at $2,974,891.22. This represents a 4.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the transaction, the insider owned 110,261 shares in the company, valued at $841,291.43. The trade was a 6.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 39,195 shares of company stock valued at $299,058. Company insiders own 0.70% of the company’s stock.

Teladoc Health Trading Up 2.4%

Shares of TDOC opened at $6.51 on Friday. The company’s fifty day simple moving average is $7.94 and its 200 day simple moving average is $6.64. Teladoc Health, Inc. has a 1-year low of $4.40 and a 1-year high of $9.89. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -6.58 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%.The firm had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. During the same quarter in the prior year, the company earned ($0.19) earnings per share. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, research analysts forecast that Teladoc Health, Inc. will post -0.89 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TDOC. Bank of America lifted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Canaccord Genuity Group lowered their target price on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Citigroup cut their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.54.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.